Michael Method

Trials

Studies that name Michael Method as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:13 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT04296890 · A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

  ImmunoGen, Inc. · completed · Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer · study director
• Ph2
  NCT00503581 · Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia

  Gynecologic Oncology Group · terminated · High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 16:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• GYNECOLOGIC ONCOLOGY GROUP
  U10CA101165 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI Philip J. DiSaia · fiscal years 2003 to 2014
  Named on NCT00503581